Adagene Aktie - ADAG

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

2,09

Gebot

2,05

Fragen

2,15

Volumen

3.362

2,09 Tagesbereich 2,10

0,00 52-Wochen-Bereich 0,00

Marktkapitalisierung

92,204M

Handelsende

2,06

Handelsbeginn

2,10

Letzte Trade

100

2.09

Letzter Handelszeitpunkt

16:22:33

Finanzvolumen

US$ 7.056

VWAP

2,0987

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

44.116.671

Dividendenrendite

Kurs-Gewinn-Verhältnis

-4,89

Gewinn pro Aktie (EPS)

-0,43

Erlöse

21,59M

Nettogewinn

-18,95M

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reacti... Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline. Mehr anzeigen

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Hauptsitz

Grand Cayman, Cym

Gegründet

Adagene Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ADAG. The last closing price for Adagene was US$2,06. Over the last year, Adagene shares have traded in a share price range of US$ 0,00 to US$ 0,00.

Adagene currently has 44.116.671 shares in issue. The market capitalisation of Adagene is US$90,88 million. Adagene has a price to earnings ratio (PE ratio) of -4.89.

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc

- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel...

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

ADAG - Frequently Asked Questions (FAQ)

What is the current Adagene share price?

The current share price of Adagene is US$ 2,09

How many Adagene shares are in issue?

Adagene has 44.116.671 shares in issue

What is the market cap of Adagene?

The market capitalisation of Adagene is USD 90,88M

What is the 1 year trading range for Adagene share price?

Adagene has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of Adagene?

The price to earnings ratio of Adagene is -4,89

What is the cash to sales ratio of Adagene?

The cash to sales ratio of Adagene is 4,29

What is the reporting currency for Adagene?

Adagene reports financial results in USD

What is the latest annual turnover for Adagene?

The latest annual turnover of Adagene is USD 21,59M

What is the latest annual profit for Adagene?

The latest annual profit of Adagene is USD -18,95M

What is the registered address of Adagene?

The registered address for Adagene is P. O. BOX 31119 GRAND PAVILION, HIBISCUS WAY, 802 WEST BAY ROAD, GRAND CAYMAN, KY1 - 1205

Which industry sector does Adagene operate in?

Adagene operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
GVVisionary Holdings Inc	US$ 2,30 (78,29%)	78,74M
CMRXChimerix Inc	US$ 8,405 (69,46%)	92,64M
ARBBARB IOT Group Ltd	US$ 0,792651 (52,43%)	52,26M
CDXCChromaDex Corporation	US$ 8,4986 (51,76%)	6,31M
PRTSCarParts com Inc	US$ 1,215 (37,88%)	4,25M
CUTRCutera Inc	US$ 0,1666 (-47,01%)	5,71M
LBGJLi Bang International Corporation Inc	US$ 1,30 (-35,00%)	114,77k
XCURExicure Inc	US$ 10,515 (-26,37%)	65,75k
CRWLGranite Shares 2x Long CRWD Daily ETF	US$ 22,90 (-21,06%)	276,91k
TIVCTivic Health Systems Inc	US$ 0,2741 (-19,36%)	796,03k
ADTXAditxt Inc	US$ 0,055 (10,44%)	101,65M
CMRXChimerix Inc	US$ 8,41 (69,56%)	93,88M
GVVisionary Holdings Inc	US$ 2,2901 (77,53%)	82,22M
NVDANVIDIA Corporation	US$ 115,54 (-0,39%)	73,88M
SLXNSilexion Therapeutics Corporation	US$ 1,425 (28,38%)	70,72M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Adagene Inc (ADAG) Börsenkurse

Adagene Inc (ADAG)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Adagene Inc

ADAG Neueste Nachrichten

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc

ADAG - Frequently Asked Questions (FAQ)

Beweger

ADAG Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR